



FINAL

CERVIX CANCER COMMITTEE AGENDA
WEDNESDAY, MAY 30, 2018, 3:00PM – 4:30PM
CHAIR: BRAD MONK CO-CHAIR: ANTONIO CASADO
EXHIBIT HALL, PALMER HOUSE HILTON HOTEL, CHICAGO
HARMONIZATION LIAISONS: STONEBRAKER/KELLER (OPS), REUSS (STATS)
Please sign Attendance Forms

WELCOME & INTRODUCTIONS MONK
COI DECLARATIONS
APPROVAL OF MINUTES/REPORT: NOVEMBER 2017 (POSTED ON GCIG WEBSITE)
MOTION: _____ SECONDED: _____

CLOSED/PUBLISHED TRIALS: MONK

- Impact of Tumour Histology on survival in advanced cervical carcinoma:
an NRG Oncology/Gynaecologic Oncology Group Study
Br J Cancer. 2018 Jan; 118(2):162-170

ON-GOING CLINICAL TRIALS:

a) ANZGOG OUTBACK EXCISE	MILESHKIN
b) BGOG ENGOT-CX1 RANDOMIZED PHASE II OF PACLITAXEL-CARBOPLATIN +/- NINTEDANIB	VERGOTE
c) CCTG CONTESSA / NEOCON-F SHAPE	PLANTE PLANTE
d) DGOG GROINSS-VII GROINSS-VIII	CREUTZBERG CREUTZBERG
e) GINECO SENTICOL III	LECURU
f) NRG/GOG-F NRG 278 GOG 3009 NRG GY006 NRG 279 GOG 3016 RTOG 0724	MONK MONK MONK MONK MONK MONK
g) KGOG GOG 263 TACO	RYU RYU
h) NCRI INTERLACE	McCORMACK

UPDATE OF TRIALS IN DEVELOPMENT:

- Excisional treatment in women with cervical adenocarcinoma-in-situ(AIS):
A prospective randomised controlled non-inferiority trial to compare AIS recurrence after loop electrosurgical excision procedure (LEEP) to cold knife cone biopsy (CKC)

Cohen

NEW CONCEPTS/PROPOSALS:

- AGOG: A Phase 2 Trial of Pembrolizumab combined with chemoradiation in patients with [¹⁸F]-FDG PET/CT-defined poor-prognostic cervical cancer

Lai

DISCUSSION/FUTURE DIRECTIONS:

MONK/CASADO

ADJOURN